Globes

Outlet metrics

Domain Authority

Ranking

Global

N/A

Country

N/A

Articles

UBS: Israel rises in global wealth rankings

1 week ago | en.globes.co.il | Simon Griver

Average wealth per adult in Israel rose 7.8% in real terms in 2024, the Swiss bank reports. Israel was ranked 17th in the UBS 2025 Global Wealth Report with average wealth of $284,000 per adult in 2024, up 7.8% in real terms, measured in local currency, from 2023 when Israel was ranked 18th. The Swiss bank said that median wealth in Israel in 2024 grew by over 12%, while median wealth skyrocketed 30%, the fifth highest performance in 2024 in the UBS sample of 56 countries.
PolyPid reports positive phase 3 surgical infection drug trial

2 weeks ago | en.globes.co.il | Dikla Czaczkes Akselbrad |Gali Weinreb

The Israeli company's treatment is a delayed-release antibiotic administered in the area where the patient has undergone surgery. Israeli late-stage biopharmaceutical company PolyPid (Nasdaq: PYPD) has reported positive Phase III trial results on its treatment for surgical infections. In 2022, PolyPid's previous trial of the drug failed, which saw its share price fall 77% in one day and continue falling since. Yesterday the share price rose 2.75%, giving a market cap of $34.24 million.
NIO revives Better Place-style battery swap station network

3 weeks ago | en.globes.co.il | Dubi Ben-Gedalyahu

Move-up buyers get bigger tax window to sell old home Mortgage taking in Israel remains strong The Chinese carmaker is setting up a battery switching station network in Israel, 15-years after Better Place went bankrupt. Preparations are currently being completed for the establishment of the first rapid battery switching station in Israel for the electric vehicles of Chinese car manufacturer NIO.
Teva gives aggressive guidance for innovative drugs

1 month ago | en.globes.co.il | Richard Francis |Gali Weinreb

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) held an "Innovation and Strategy Day" today, in which it discussed the future of its (non-generic) biopharmaceutical activity. The company sees revenue from its three leading drugs: Austedo, for treating involuntary movements; migraine prevention treatment Ajovy; and long-acting schizophrenia treatment Uzedy, reaching at least $5 billion by 2030. This compares with $2 billion for the three products combined in 2024.
"I expected a million; we received $125m"

1 month ago | en.globes.co.il | Gali Weinreb

Israeli universities do not generally disclose the lists of their donors and how much they have raised, but in the past year three of them boasted especially high contributions. The latest was Tel Aviv University.
Calls to exclude Israel from Horizon jeopardize research

1 month ago | en.globes.co.il | Gali Weinreb

Apartments sold and rented Israel claims Sanaa Airport out of action With the EU discussing proposals to end Israel's participation in the Horizon program, and the Trump administration cutting international grants, Israeli researchers fear for the future. Israel's exclusion from the EU's Horizon Europe research and innovation program and its support for science, as is being discussed, would set Israeli science back years and relegate its status.
Chinese share of Israeli car market highest in developed world

1 month ago | en.globes.co.il | Dubi Ben-Gedalyahu

US tax changes hit renewable energy cos El Al, Israir stocks gain strongly as foreign carriers cancel Chinese made vehicles are seen reaching 30% of all deliveries in Israel by the end of the year. In the first quarter of 2025, the market share taken by Chinese-produced vehicles in Israel was the highest in all the world’s developed markets.
Israeli companies streamlining US healthcare

1 month ago | en.globes.co.il | Gali Weinreb

Is Nice ready to bounce back? Iron Beam - world's most powerful laser defense system Over the past 15 years, Israeli startups have been applying Big Data to cure the US healthcare system’s ills. How do they do it, and can they maintain their advantage? Israel’s biomedical industry is undergoing among its most difficult periods, but two sub-sectors are still managing to keep their heads above water.
Qiagen buys Israeli AI software co Genoox

1 month ago | en.globes.co.il | Gali Weinreb

US diagnostics giant Qiagen has announced that it has signed a definitive agreement to acquire Israeli AI software company Genoox for $80 million, including an immediate payment of $70 million and a further $10 million in milestone payments. Genoox, which has 55 employees, will become Qiagen's Israel development center and will expand by hiring more development and software staff.
S&P retains negative outlook for Israel rating - Globes

1 month ago | en.globes.co.il | Oren Dori

The credit rating agency notes the strengths of Israel's economy, but sees current geopolitical risks as decisive.